Incyte Corporation

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
53.06 ^USD	-0.82%		-1.30%	-15.50%

May. 07	Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	MT
May. 01	TD Cowen Adjusts Price Target on Incyte to $80 From $88	MT

Incyte : to Present at Upcoming Investor Conference

December 09, 2020 at 08:01 am EST

Incyte (Nasdaq:INCY) announced today that it will present at the 39^th Annual J. P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 7:30 a.m. EST.

The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 90 days.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005032/en/

Latest news about Incyte Corporation

Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	May. 07	MT
TD Cowen Adjusts Price Target on Incyte to $80 From $88	May. 01	MT
RBC Capital Adjusts Price Target on Incyte to $60 From $65	May. 01	MT
Piper Sandler Adjusts Price Target on Incyte to $80 From $85	May. 01	MT
Goldman Sachs Adjusts Price Target on Incyte to $60 From $63	May. 01	MT
Leerink Partners Adjusts Price Target on Incyte to $80 From $83, Keeps Outperform Rating	May. 01	MT
Citigroup Adjusts Price Target on Incyte to $80 From $81	May. 01	MT
BMO Capital Adjusts Incyte Price Target to $52 From $56	May. 01	MT
Truist Securities Trims Incyte's Price Target to $83 From $84, Buy Rating Maintained	Apr. 30	MT
Incyte's Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed	Apr. 30	MT
Transcript : Incyte Corporation, Q1 2024 Earnings Call, Apr 30, 2024	Apr. 30
Earnings Flash (INCY) INCYTE Posts Q1 Revenue $880.9M, vs. Street Est of $924.6M	Apr. 30	MT
Earnings Flash (INCY) INCYTE Posts Q1 EPS $0.64, vs. Street Est of $0.83	Apr. 30	MT
Incyte Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 30	CI
Incyte Corporation Maintains Revenue Guidance for 2024	Apr. 30	CI
Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating	Apr. 24	MT
Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call	Apr. 23
Incyte Corporation entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.	Apr. 22	CI
BMO Capital Adjusts Price Target on Incyte to $56 From $64	Apr. 19	MT
Incyte, China Medical System Sign Collaboration, License Agreement	Apr. 01	MT
Incyte Corporation and China Medical System Holdings Limited Announce Collaboration and License Agreement for Povorcitinib, an Oral Jak1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	Apr. 01	CI
Trial of Insider Trading Case Against Former Medivation Employee Begins in California	Mar. 26	MT
Incyte's Povorcitinib Potentially Suited for Hidradenitis Suppurativa, Prurigo Nodularis, RBC Says	Mar. 12	MT
Transcript : Incyte Corporation - Shareholder/Analyst Call	Mar. 11
Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)	Mar. 10	CI

Chart Incyte Corporation

Duration

Period

More charts

Company Profile

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

Pharmaceuticals

Calendar

2024-05-15 - BofA Securities Health Care Conference

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Incyte Corporation : Is a big change imminent?

October 26, 2023 at 10:00 am EDT

More Strategies

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

53.06 USD

Average target price

73.35 USD

Spread / Average Target

+38.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
INCYTE CORPORATION	-15.50%	12.01B
CSL LIMITED	-2.61%	88.47B
SAMSUNG BIOLOGICS CO.,LTD.	+3.55%	40.71B
BIOGEN INC.	-14.40%	32.43B
UCB	+55.89%	24.28B
BIOMARIN PHARMACEUTICAL INC.	-15.96%	15.52B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-41.29%	12.17B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.75%	12B
SWEDISH ORPHAN BIOVITRUM AB	+7.87%	8.87B
INNOVENT BIOLOGICS, INC.	-3.16%	8.44B

Biopharmaceuticals

Incyte Corporation

Equities

INCY

US45337C1027

Pharmaceuticals

Incyte : to Present at Upcoming Investor Conference

EPS Revisions